00:00As the Minarini Group, we are proud to have undertaken, a few years ago, this path of commitment to research and the development of drugs in the hematological field.
00:15Today we are here to share the recent approval of the Agency of Pharmacy for a new molecule, a first-in-class, non-inhibitor of protein XPO1, Selnexor,
00:27which has received two indications, one in the early lines, with a triple association of Selnexor with Bortezomib and Dexamethasone,
00:38for the first-in-class patients, and one in the advanced lines, for patients with pentarefractories, in association with Solodexamethasone.
00:47This therapeutic innovation follows that of Tagraxopus, which is a target therapy inhibitor of CD123, which received approval last year for patients affected by PPD-CN,
00:59an orphan, but lethal pathology, and which requires a multidisciplinary approach for a correct diagnosis path,
01:11and Tagraxopus certainly represents an additional therapeutic innovation at the disposal of patients in an attempt to be resuscitated to a transplant condition.
01:23All this has been made possible thanks to a close collaboration with the Excellence of Italian Hematology, with the Academy, the University,
01:35and the next steps will certainly go in this direction, trying to bring as much innovation as possible for patients affected by blood tumors.
Comments